← ARROWHEAD PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($81.7m) |
($34.4m)
+57.93%
|
($54.5m)
-58.38%
|
$68.0m
+224.84%
|
($84.6m)
-224.39%
|
($140.8m)
-66.58%
|
($176.1m)
-25.00%
|
($205.3m)
-16.59%
|
($599.5m)
-192.04%
|
($1.6m)
+99.73%
|
— | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($81.7m) | ($34.4m) | ($54.5m) | $68.0m | ($84.6m) | ($140.8m) | ($176.5m) | ($209.3m) | ($609.7m) | $30.1m | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | — | — | ($431k) | ($4.0m) | ($10.2m) | $31.7m | — | |
| Depreciation, Depletion and Amortization | $3.3m | $4.7m | $4.7m | $2.7m | $4.2m | $6.6m | $8.7m | $10.7m | $16.9m | $22.2m | $25.8m | |
| Depreciation | $3.3m | $4.7m | $3.0m | $4.4m | $5.9m | $8.3m | $10.4m | $12.5m | $18.6m | $23.9m | $25.8m | |
| Amortization of Intangible Assets | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | $0 | $0 | $0 | $0 | — | |
| Share-based Payment Arrangement, Noncash Expense | $11.6m | $7.9m | $8.5m | $12.4m | $43.4m | $76.7m | $120.9m | $78.1m | $74.0m | $63.4m | $70.0m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $634k | $439k | $55k | — | — | — | — | — | — | — | — | |
| Share-based Payment Arrangement, Expense | $11.6m | $7.9m | — | — | — | — | — | — | $67.1m | $54.8m | $70.0m | |
| Impairment of Intangible Assets (Excluding Goodwill) | $945k | — | — | — | — | — | — | — | — | — | — | |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | — | — | $0 | $0 | $0 | $0 | — | |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | $945k | — | — | — | — | — | — | — | — | — | — | |
| Nonoperating Income (Expense) | $22k | $2.6m | $1.5m | $7.0m | $8.6m | $8.2m | $5.8m | ($1.5m) | ($11.4m) | ($46.8m) | — | |
| Other Nonoperating Income (Expense) | $57k | $1.3m | $7k | — | ($583k) | $2.1m | $765k | $1.5m | ($1.7m) | $5.3m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $75k | ($7k) | $260k | $334k | $184k | $9.4m | ($8.8m) | ($1.4m) | $0 | $57.0m | ($49.0m) | |
| Increase (Decrease) in Accounts Payable | $2.6m | ($3.5m) | ($1.3m) | $4.8m | ($821k) | $2.6m | ($6.6m) | $33.0m | ($5.5m) | $6.3m | ($5.4m) | |
| Net Cash Provided by (Used in) Operating Activities | ($64.4m) |
($23.9m)
+62.84%
|
($47.2m)
-97.27%
|
$173.0m
+466.42%
|
($95.4m)
-155.13%
|
$171.2m
+279.50%
|
($136.1m)
-179.50%
|
($153.9m)
-13.05%
|
($462.9m)
-200.77%
|
$179.6m
+138.79%
|
($59.1m)
-132.89%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $3.9m | $7.9m | $1.4m | $12.0m | $12.0m | $23.6m | $52.8m | $176.7m | $141.5m | $22.7m | ($16.1m) | |
| Gain (Loss) on Investments | — | — | — | — | — | — | ($4.4m) | $0 | — | — | ($3.2m) | |
| Payments to Acquire Investments | — | — | — | — | $279.0m | $240.7m | $223.4m | $246.1m | $720.9m | $796.3m | ($1.2b) | |
| Net Cash Provided by (Used in) Investing Activities | $13.4m | ($48.6m) | ($7.4m) | ($47.7m) | ($240.8m) | ($141.7m) | ($5.4m) | ($96.2m) | ($420.1m) | ($129.3m) | ($801.7m) | |
| Cash flows from financing activities: | ||||||||||||
| Proceeds from Issuance of Common Stock | $52.2m | $12.4m | $56.6m | $60.5m | $250.5m | $0 | $0 | $0 | $429.3m | $241.4m | $76.1m | |
| Net Cash Provided by (Used in) Financing Activities | $55.1m |
$12.1m
-78.13%
|
$60.0m
+397.32%
|
$66.4m
+10.72%
|
$257.9m
+288.58%
|
$11.3m
-95.62%
|
$65.2m
+476.61%
|
$253.1m
+288.20%
|
$870.5m
+244.01%
|
$74.0m
-91.50%
|
$784.2m
+959.63%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | $191.7m | ($78.2m) | $40.9m | ($67k) | ($122k) | $4.2m | ($401k) | $53.2m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | ($78.6m) | $40.9m | $108.0m | $110.9m | $102.7m | $226.5m | $53.2m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $410k | ($88k) | ($67k) | ($122k) | $4.2m | ($401k) | $1.6m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | — | $3.6m | $8.3m | $7.5m | $11.3m | $5.2m | $3.1m | $2.4m | $4.0m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | ($11k) | ($188k) | $173k | $27k | $0 | $0 | $0 | $0 | $0 | $19k | — | |
| Income Taxes Paid, Net | ($2k) | ($2k) | ($2k) | ($302k) | $103k | ($2k) | ($2k) | $0 | ($3.7m) | $814k | — | |
| Additional Financial Items | ||||||||||||
| General and Administrative Expense | $9.9m | $6.8m | $19.1m | $26.6m | $52.3m | $81.0m | $124.4m | $92.5m | $98.8m | $123.9m | — | |
| Income Tax Expense (Benefit) | $2k | $2k | $2k | $174k | $2k | $2k | $3.8m | $2.8m | ($2.8m) | $21.4m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $32.4m | $89.4m | — | |
| Operating Expenses | $81.9m | $68.4m | $72.1m | $107.6m | $181.2m | $287.3m | $421.7m | $445.7m | $604.6m | $731.1m | — | |
| Proceeds from Contributed Capital | — | — | — | — | — | — | $60.0m | $0 | $0 | — | — | |
| Realized Investment Gains (Losses) | — | — | — | — | — | — | — | — | ($80k) | $0 | — | |
| Unrealized Gain (Loss) on Derivatives | ($301k) | $890k | $432k | — | — | — | — | — | — | — | — |